Find Funding Opportunities

Find Funding Opportunities

Returning 148 results
Filter By:

Multidisciplinary Studies of HIV/AIDS and Aging (R01 Clinical Trial Optional)

PAR
Wednesday, November 29, 2017
Clinical Trials Research
Tuesday, September 8, 2020
R01
PAR-18-189

Funding Opportunity Purpose

This FOA encourages applications at the intersection of HIV and aging by addressing two overarching objectives: 1) to improve understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) to improve approaches for testing, prevention, and treatment of HIV infection, and management of HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying our current understanding of aging science. Applications appropriate to this FOA should be consistent with the scientific priorities outlined by the NIH Office of AIDS Research (OAR) as described in NOT-OD-15-137.

Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional)

PAR
Wednesday, November 29, 2017
Clinical Trials Research
Tuesday, September 8, 2020
R21
PAR-18-190

Funding Opportunity Purpose

This FOA encourages exploratory/developmental research applications at the intersection of HIV and aging by addressing two overarching objectives: 1) to improve understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) to improve approaches for testing, prevention, and treatment of HIV infection, and management of HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying our current understanding of aging science. Applications appropriate to this FOA should be consistent with the scientific priorities outlined by the NIH Office of AIDS Research (OAR) as described in NOT-OD-15-137.

NINDS Efficacy Clinical Trials (U01) - Clinical Trial Required

PAR
Wednesday, November 29, 2017
Clinical Trials Research
Friday, January 8, 2021
U01
PAR-18-422

Funding Opportunity Purpose

The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated efficacy clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The trials must address questions within the mission and research interests of the NINDS and may evaluate drugs, biologics, and devices, as well as surgical, behavioral and rehabilitation therapies. Information about the mission and research interests of the NINDS can be found at the NINDS website (http://www.ninds.nih.gov/)

NINDS Exploratory Clinical Trials (U01 - Clinical Trials Required)

PAR
Wednesday, November 29, 2017
Clinical Trials Research
Wednesday, January 8, 2020
R01
PAR-18-420

Funding Opportunity Purpose

The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated exploratory clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The trials must address questions within the mission and research interests of the NINDS and may evaluate drugs, biologics, and devices, as well as surgical, behavioral and rehabilitation therapies. Information about the mission and research interests of the NINDS can be found at the NINDS website (http://www.ninds.nih.gov/)

NINDS Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional)

PA
Wednesday, November 15, 2017
Friday, January 8, 2021
R21
PA-18-358

Funding Opportunity Purpose

The NINDS Exploratory Neuroscience Research Grant program supports exploratory and innovative research projects, which fall within the mission of the NINDS. Awards will provide support for the early and conceptual stages of projects. These studies often assess the feasibility of a novel avenue of investigation and involve considerable risk, but have the potential to bring about breakthroughs in the understanding of important areas of neuroscience, or to the development of novel techniques, agents, methodologies, or models, of high value to the neuroscience community.

Zika Virus (ZIKV) Complications (R21 Clinical Trial Optional)

PA
Wednesday, November 15, 2017
Wednesday, January 8, 2020
R21
PA-18-048

Funding Opportunity Purpose

The purpose of this Funding Opportunity Announcement (FOA) is to provide support for research on Zika virus (ZIKV) and its complications. This FOA replaces PAR-16-106 which had used rolling application due dates to facilitate the rapid review and award of particularly urgent or time-sensitive projects. The last date for submitting an application to PAR-16-106 is January 13, 2017.

Translational Neural Devices (U44 - Clinical Trial Required)

RFA
Wednesday, November 8, 2017
Translational Research, Clinical Trials Research
Thursday, October 22, 2020
U44
RFA-NS-18-012

Funding Opportunity Purpose

The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from Small Business Concerns (SBCs) to pursue translational activities and small clinical studies to advance the development of therapeutic and diagnostic devices for disorders that affect the nervous or neuromuscular systems. The translational device activities, including translational bench and animal studies, are expected to lead to submission of an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) or Institutional Review Board (IRB) application for a Non-Significant Risk (NSR) study. This cooperative agreement will also support the subsequent small clinical study to collect safety and effectiveness data required to support a marketing application or to inform final device design.

Translational Neural Devices (UG3/UH3 - Clinical Trial Required)

RFA
Wednesday, November 8, 2017
Translational Research
Thursday, October 22, 2020
UG3/UH3
RFA-NS-18-011

Funding Opportunity Purpose

The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to pursue translational activities and small clinical studies to advance the development of therapeutic, and diagnostic devices for disorders that affect the nervous or neuromuscular systems. The translational device activities, including translational bench and animal studies, are expected to lead to submission of an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) or Institutional Review Board (IRB) application for a Non-Significant Risk (NSR) study. This cooperative agreement will also support the subsequent small clinical study to collect safety and effectiveness data required to support a marketing application or to inform final device design.

NIH SIREN Neurologic Clinical Trials (U01 Clinical Trial Required)

PAR
Tuesday, October 3, 2017
Friday, January 8, 2021
U01
PAR-18-304

Funding Opportunity Purpose

This funding opportunity announcement (FOA) encourages applications for multi-center clinical trials focused on neurological emergencies. Successful applicants will collaborate and conduct the trial within the NIH SIREN Network. The NIH SIREN Clinical Coordinating Center (CCC) will work with the successful applicants to implement the proposed trial efficiently and the SIREN Data Coordinating Center (DCC) will provide statistical and data management support. The NIH SIREN hubs and their affiliated clinical sites will provide on-site implementation of the clinical protocols.

NINDS CREATE Bio Optimization Track for Biologics (U01)

PAR
Monday, August 14, 2017
Translational Research
Tuesday, September 8, 2020
U01
PAR-17-456
Chris Boshoff

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) supports the optimization of potential therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene and cell therapies) for disorders identified under the NINDS mission. This track supports the further characterization and optimization of therapeutic lead(s) that showed promise as a potential therapeutic agent as evidenced by convincing animal proof-of-concept studies. Therefore, at the end of this funding period, successful projects will have delivered and optimized therapeutic candidate with demonstrated bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and should be eligible for entry into the CREATE Bio Development track. The CREATE Bio Development track is a later stage program focused on the development of optimized therapeutic candidates through Investigational New Drug (IND)-enabling studies and submission of an IND package to the Food and Drug Administration (FDA).

Pages